PODCAST: China’s Burgeoning Debt, and a New Type of China IPO
By Doug Young & Rene Vanguestaine
China’s debt-to-GDP ratio swelled to 288% last year, up 13.5 basis points and a huge level by any standard. Is this kind of debt level sustainable, or will something have to give? And a company called Arrivent has just listed in New York, banking on its licensing deal for a made-in-China cancer drug to make its own big money by selling the drug in the U.S. What’s the China risk behind this kind of company?
About China Inc
China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.
Subscribe to China Inc on your favorite app:
Related Articles
RELATED ARTICLES
-
CHINA BULLETIN: Local Governments Crushed by Debt
- CHINA BULLETIN: China-U.S. Rapprochement Continues with Xi-Biden Call, Yellen Visit
- CHINA BULLETIN: GDP Rebounds, as Putin Comes Calling
- CHINA BULLETIN: Economic Growth Target Stays at 5%
- CHINA BULLETIN: China Eases Up on Cross-Border Data Requirements
- CHINA BULLETIN: Bring on the Equipment Upgrades, Says Beijing
